Soler-Palacín Pere, Martín-Nalda Andrea, Martínez-Gómez Xavier, Melendo Susana, Riudor Encarnació, Arranz Jose Antonio, Espiau Maria, Figueras Concepció
Pediatric Infectious Diseases and Immunodeficiencies Unit, Hospital Universitari Vall d'Hebron and Universitat Autònoma de Barcelona, Barcelona, Spain.
AIDS Res Hum Retroviruses. 2012 Aug;28(8):752-8. doi: 10.1089/AID.2011.0198. Epub 2011 Nov 16.
Perinatal antiretroviral (ARV) exposure has been related to hyperlactatemia and lactic acidosis in infants born to HIV-infected mothers. Our objective was to determine the incidence of these conditions during the first year of life in uninfected infants born to HIV-infected mothers and compare the data with infants born to mothers with hepatitis C virus (HCV) infection. We investigated the relationships between hyperlactatemia and neurological and neurodevelopmental disorders by conducting a prospective, comparative cohort study (October 2004 to October 2007) consecutively including children of HIV- and HCV-infected mothers. Liver enzymes, pH, lactic acid, and plasma amino acids were determined at 1.5, 3, 6, and 12 months of life. Pathological hyperlactatemia was defined as lactate >2.1 mmol/liter together with alanine >475 μmol/liter. Seventy-nine patients (39 HIV-exposed patients and 40 unexposed patients) were included. Baseline maternal characteristics in the two groups were similar. Almost 90% of HIV-infected mothers received HAART during gestation, while 10.3% were given AZT monotherapy. Eight newborns received combined therapy and 31 received AZT-based monotherapy. Twelve patients (five exposed and seven nonexposed) had some neurological disorder, and four other patients (one vs. three) showed signs of neurodevelopmental delay, with no significant differences between the groups (p=0.34). Pathological hyperlactatemia was detected in 56.4% (95% CI 39.6-72.2) and 57.5% (95% CI 40.9-73.0) of patients, respectively (p=0.92), and this condition was more frequent in preterm children (p<0.05). ARV use during pregnancy and the neonatal period was not associated with pathological hyperlactatemia. The presence of hyperlactatemia was not associated with neurological or neurodevelopmental disorders. No association was established between the use of ARV agents and the development of hyperlactatemia or neurological disorders in HIV-exposed children during their first year of life.
围产期接触抗逆转录病毒药物(ARV)与感染HIV的母亲所生婴儿的高乳酸血症和乳酸性酸中毒有关。我们的目的是确定感染HIV的母亲所生未感染婴儿在出生后第一年出现这些情况的发生率,并将数据与丙型肝炎病毒(HCV)感染母亲所生婴儿的数据进行比较。我们通过进行一项前瞻性比较队列研究(2004年10月至2007年10月),连续纳入感染HIV和HCV的母亲的子女,研究高乳酸血症与神经及神经发育障碍之间的关系。在婴儿1.5、3、6和12个月时测定肝酶、pH值、乳酸和血浆氨基酸。病理性高乳酸血症的定义为乳酸>2.1 mmol/升且丙氨酸>475 μmol/升。共纳入79例患者(39例接触HIV的患者和40例未接触HIV的患者)。两组的基线母亲特征相似。几乎90%感染HIV的母亲在孕期接受了高效抗逆转录病毒治疗(HAART),而10.3%接受了齐多夫定(AZT)单一疗法。8名新生儿接受了联合治疗,31名接受了以AZT为基础的单一疗法。12例患者(5例接触组和7例未接触组)有一些神经障碍,另外4例患者(1例接触组对3例未接触组)有神经发育延迟迹象,两组之间无显著差异(p = 0.34)。分别在56.4%(95%可信区间39.6 - 72.2)和57.5%(95%可信区间40.9 - 73.0)的患者中检测到病理性高乳酸血症(p = 0.92),这种情况在早产儿中更常见(p < 0.05)。孕期和新生儿期使用ARV与病理性高乳酸血症无关。高乳酸血症的存在与神经或神经发育障碍无关。在感染HIV的儿童出生后第一年,未发现ARV药物的使用与高乳酸血症或神经障碍的发生之间存在关联。